Editorial: The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines

Therapeutic Advances in Cardiovascular Disease

Volumn 2, Issue 1, 2008, Pages 5-12

  Mancia, Giuseppe ^a   Grassi, Guido ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DYSLIPIDEMIA; EDITORIAL; EVIDENCE BASED MEDICINE; GLUCOSE METABOLISM; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MEDICAL SOCIETY; METABOLIC SYNDROME X; OBESITY; ORGAN INJURY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TARGET ORGAN; WEIGHT GAIN; CARDIOLOGY; EUROPE; STANDARD;

CARDIOLOGY; EUROPE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC;

EID: 59049101119     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944707087409     Document Type: Editorial

References (33)

1. Bergman, R.N., Kim, S.P., Hsu, I.R., Catalano, K.J., Chiu, J.D., Kabir, M. et al. (2007) Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 120: S3–S8.
2. Bradley, H.A., Wiysonge, C.S., Volmink, J.A., Mayosi, B.M., Opie, L.H. (2006) How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 24: 2131–2141.
3. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G., de Faire, U. et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003.
4. Dahlof, B., Sever, P.S., Poulter, N.R., Wedel, H., Beevers, D.G., Caulfield, M. et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 366: 895–906.
5. Gerdts, E., Wachtell, K., Omvik, P., Otterstad, J.E., Oikarinen, L., Boman, K. et al. (2007) Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. Hypertension 49: 311–316.
6. Grassi, G., Arenare, F., Quarti Trevano, F., Dell'Oro, R., Mancia, G. (2007) Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials. Curr Hypertens Rep 9: 299–304.
7. Guidelines Committee (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011–1053.
8. Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlöf, B., Elmfeldt, D., Julius, S. et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351: 1755–1762.
9. Hayden, M., Pignone, M., Phillips, C., Mulrow, C. (2002) Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 136: 161–172.
10. Hodis, H.N., Mack, W.J., LaBree, L., Selzer, R.H., Liu, C.R., Liu, C.H. et al. (1998) The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128: 262–269.
11. Jafar, T.H., Stark, P.C., Schmid, C.H., Landa, M., Maschio, G., de Jong, P.E. et al. (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139: 244–252.
12. Levy, D., Garrison, R.J., Savage, D.D., Kannel, W.B., Castelli, W.P. (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561–1566.
13. Lindholm, L.H., Carlberg, B., Samuelsson, O. (2005) Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553.
14. Mancia, G. (2006) Total cardiovascular risk: a new treatment concept. J Hypertens Suppl 24: S17–S24.
15. Mancia, G., de Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G. et al. (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105–1187.
16. Mancia, G., Grassi, G., Zanchetti, A. (2006) New-onset diabetes and antihypertensive drugs. J Hypertens 24: 3–10.
17. Mancia, G., Lanfranchi, A., Turri, C., Grassi, G. (1998) Can good surrogate end-points predict the prognosis of hypertensive patients? J Hypertens Suppl 16: S3–S7.
18. McKenna, M., Wolfson, S., Kuller, L. (1991) The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 87: 119–128.
19. Messerli, F.H., Mancia, G., Conti, C.R., Hewkin, A.C., Kupfer, S., Champion, A. et al. (2006) Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous ? Ann Intern Med 144: 884–893.
20. Muiesan, M.L., Salvetti, M., Monteduro, C., Bonzi, B., Paini, A., Viola, S. et al. (2004) Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 43: 731–738.
21. Nice/Bhs (2006) Hypertension: management of hypertension in adults in primary care NICE/BHS. www.nice.org.uk/CG034.
22. O'Leary, D.H., Polak, J.F., Kronmal, R.A., Manolio, T.A., Burke, G.L., Wolfson, Jr, S.K. (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340: 14–22.
23. Pepine, C.J., Handberg, E.M., Cooper-De Hoff, R.M., Marks, R.G., Kowey, P., Messerli, F.H. et al. (2003) A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290: 2805–2816.
24. Prospective Studies Collaboration (2002) Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903–1913.
25. Schrader, J., Luders, S., Kulschewski, A., Hammersen, F., Plate, K., Berger, J. et al. (2005) Morbidity and Mortality After Stroke. Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218–1226.
26. Schrader, J., Luders, S., Kulschewski, A., Berger, J., Zidek, W., Treib, J. et al. (2003) The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 34: 1699–1703.
27. Sever, P.S., Dahlof, B., Poulter, N.R., Wedel, H., Beevers, G., Caulfield, M. et al. (2003) The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet 361: 1149–1158.
28. Sharma, A.M., Pischon, T., Hardt, S., Kunz, I., Luft, F.C. (2001) Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37: 250–254.
29. Staessen, J.A., Wang, J.G., Thijs, L. (2003) Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 21: 1055–1076.
30. Torp-Pedersen, C., Metra, M., Charlesworth, A. et al. (2007) Effects of metoprolol and carvedilol on preexisting and new onset diabetes in patients with chronic heart failure Data from the Carvedilol or metoprolol European Trial (COMET). Heart 93: 968–973.
31. Trenkwalder, P., Elmfeldt, D., Hofman, A., Spark, P., Lukas, M.A., Poole-Wilson, P.A. et al. (2005) The Study on Cognition and Prognosis in the Elderly (SCOPE) – major cardiovascular events and stroke in subgroups of patients. Blood Press 14: 31–37.
32. Verdecchia, P., Angeli, F., Borgioni, C., Gattobigio, R., de Simone, G., Devereux, R.B. et al. (2003) Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 16: 895–899.
33. Willum-Hansen, T., Staessen, J.A., Torp-Pedersen, C., Rasmussen, S., Thijs, L., Ibsen, H. et al. (2006) Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 113: 664–670.